DK0627924T3 - Sammensætning, der omfatter koagulationsfaktor VIII formulering, fremgangsmåde til dens fremstilling og anvendelse af et overfladeaktivt middel som stabilisator - Google Patents

Sammensætning, der omfatter koagulationsfaktor VIII formulering, fremgangsmåde til dens fremstilling og anvendelse af et overfladeaktivt middel som stabilisator

Info

Publication number
DK0627924T3
DK0627924T3 DK93923080T DK93923080T DK0627924T3 DK 0627924 T3 DK0627924 T3 DK 0627924T3 DK 93923080 T DK93923080 T DK 93923080T DK 93923080 T DK93923080 T DK 93923080T DK 0627924 T3 DK0627924 T3 DK 0627924T3
Authority
DK
Denmark
Prior art keywords
stabilizer
preparation
composition
surfactant
factor viii
Prior art date
Application number
DK93923080T
Other languages
Danish (da)
English (en)
Inventor
Thomas Oesterberg
Angelica Fatouros
Original Assignee
Genetics Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9202878A external-priority patent/SE9202878D0/xx
Priority claimed from SE9301580A external-priority patent/SE9301580D0/xx
Priority claimed from SE9302006A external-priority patent/SE9302006D0/xx
Application filed by Genetics Inst filed Critical Genetics Inst
Application granted granted Critical
Publication of DK0627924T3 publication Critical patent/DK0627924T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/829—Blood
    • Y10S530/83—Plasma; serum

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK93923080T 1992-10-02 1993-10-01 Sammensætning, der omfatter koagulationsfaktor VIII formulering, fremgangsmåde til dens fremstilling og anvendelse af et overfladeaktivt middel som stabilisator DK0627924T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
SE9202878A SE9202878D0 (sv) 1992-10-02 1992-10-02 Protein formulation
SE9301580A SE9301580D0 (sv) 1993-05-07 1993-05-07 Protein formulation
SE9302006A SE9302006D0 (sv) 1992-10-02 1993-06-11 Protein formulation
PCT/SE1993/000793 WO1994007510A1 (en) 1992-10-02 1993-10-01 Composition comprising coagulation factor viii formulation, process for its preparation and use of a surfactant as stabilizer

Publications (1)

Publication Number Publication Date
DK0627924T3 true DK0627924T3 (da) 2001-04-30

Family

ID=27355693

Family Applications (1)

Application Number Title Priority Date Filing Date
DK93923080T DK0627924T3 (da) 1992-10-02 1993-10-01 Sammensætning, der omfatter koagulationsfaktor VIII formulering, fremgangsmåde til dens fremstilling og anvendelse af et overfladeaktivt middel som stabilisator

Country Status (19)

Country Link
US (2) US5733873A (cs)
EP (3) EP1016673B1 (cs)
JP (1) JP3905921B2 (cs)
KR (1) KR100303872B1 (cs)
AT (2) ATE198277T1 (cs)
CA (1) CA2124690C (cs)
CZ (1) CZ290342B6 (cs)
DE (2) DE69333974T2 (cs)
DK (1) DK0627924T3 (cs)
ES (1) ES2154650T3 (cs)
FI (1) FI111443B (cs)
GR (1) GR3035472T3 (cs)
HU (2) HU220194B (cs)
MX (1) MX9306133A (cs)
NO (1) NO942033L (cs)
NZ (1) NZ256921A (cs)
PT (1) PT627924E (cs)
SK (1) SK282483B6 (cs)
WO (1) WO1994007510A1 (cs)

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ290342B6 (cs) * 1992-10-02 2002-07-17 Genetics Institute Inc. Kompozice stabilní při skladování, obsahující koagulační faktor VIII a neiontovou povrchově aktivní látku a způsob její výroby
SE504074C2 (sv) † 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
US6288030B1 (en) * 1993-12-22 2001-09-11 Amgen Inc. Stem cell factor formulations and methods
US6242417B1 (en) * 1994-03-08 2001-06-05 Somatogen, Inc. Stabilized compositions containing hemoglobin
IL113010A0 (en) * 1994-03-31 1995-10-31 Pharmacia Ab Pharmaceutical formulation comprising factor VIII or factor ix with an activity of at least 200 IU/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
US5514781A (en) * 1994-04-11 1996-05-07 Bayer Corporation Use of azoles as virucidal agents in solutions of biologically active proteins
US6372716B1 (en) * 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX
SE503424C2 (sv) * 1994-11-14 1996-06-10 Pharmacia Ab Process för rening av rekombinant koagulationsfaktor VIII
SE9403915D0 (sv) * 1994-11-14 1994-11-14 Annelie Almstedt Process A
US7253262B2 (en) 1995-01-19 2007-08-07 Quandrant Drug Delivery Limited Dried blood factor composition comprising trehalose
GB9501040D0 (en) * 1995-01-19 1995-03-08 Quadrant Holdings Cambridge Dried composition
US7244824B2 (en) 1995-01-19 2007-07-17 Quadrant Drug Delivery Limited Dried blood factor composition comprising trehalose
SE9501189D0 (sv) * 1995-03-31 1995-03-31 Pharmacia Ab Protein formulation
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
AUPN801296A0 (en) * 1996-02-12 1996-03-07 Csl Limited Stabilised growth hormone formulation and method of preparation thereof
US7560107B2 (en) * 1996-06-26 2009-07-14 Emory University Modified factor VIII
US5763401A (en) * 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
EP0852951A1 (de) * 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US6475725B1 (en) 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
PL198123B1 (pl) * 1999-02-22 2008-05-30 Baxter Int Kompozycja czynnika VIII bez dodatku albuminy i jej zastosowanie
US20060099685A1 (en) * 1999-04-15 2006-05-11 Yallop Christopher A Recombinant expression of factor VIII in human cells
EP1194161B1 (en) 1999-07-13 2005-11-23 Biovitrum Ab Stable factor viii compositions
US6413537B1 (en) 2000-03-10 2002-07-02 Wisconsin Alumni Research Foundation Nystatin formulation having reduced toxicity
GB0207092D0 (en) 2002-03-26 2002-05-08 Sod Conseils Rech Applic Stable pharmaceutical composition containing factor VIII
AU2003293543A1 (en) * 2002-12-13 2004-07-09 Abgenix, Inc. System and method for stabilizing antibodies with histidine
JP2007505147A (ja) 2003-09-12 2007-03-08 アンティジェニクス インコーポレーテッド 単純ヘルペスウイルス感染の治療および予防用ワクチン
WO2005107776A1 (en) 2004-05-03 2005-11-17 Emory University METHOD OF ADMINISTERING PORCINE B-DOMAINLESS fVIII
KR100624013B1 (ko) * 2004-06-25 2006-09-19 주식회사 녹십자홀딩스 동결건조된 알부민 비함유 재조합 사람 혈액응고 제 8인자 제제
GB2416122A (en) * 2004-07-12 2006-01-18 Ipsen Ltd Botulinum neurotoxin composition
CN101124331B (zh) 2004-11-12 2013-04-24 拜尔健康护理有限责任公司 Fvⅲ的位点定向修饰
PT1835938E (pt) 2004-12-27 2013-11-06 Baxter Int Conjugados de polímero-factor de von willebrand
BRPI0608170A2 (pt) 2005-04-28 2010-11-09 Novo Nordisk Healthcare Ag recipiente fechado contendo uma composição de um polipeptìdeo do fator vii ativado, processo para a preparação de um recipiente fechado contendo um polipeptìdeo do fator vii ativado, kit, e, método para a preparação de uma composição farmacêutica
MY151003A (en) 2005-09-12 2014-03-31 Actelion Pharmaceuticals Ltd Stable pharmaceutical composition comprising a pyrimidine-sulfamide
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
BRPI0708832A2 (pt) 2006-03-31 2011-06-14 Baxter Int construÇço proteinÁcea
US7982010B2 (en) * 2006-03-31 2011-07-19 Baxter International Inc. Factor VIII polymer conjugates
US7645860B2 (en) * 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
US7985839B2 (en) * 2006-03-31 2011-07-26 Baxter International Inc. Factor VIII polymer conjugates
EP2364691B1 (en) 2006-06-16 2013-04-24 Regeneron Pharmaceuticals, Inc. VEGF antagonist formulations suitable for intravitreal administration
EP2532369B1 (en) 2006-12-15 2017-11-01 Baxalta GmbH Factor VIIa-(poly)sialic acid conjugate having prolonged in vivo half-life
MX2009011367A (es) 2007-04-26 2010-03-22 Bayer Healthcare Llc Estabilizacion de soluciones liquidas de proteina recombinante para el almacenamiento congelado.
PT2574677T (pt) 2007-12-27 2017-10-19 Baxalta Inc Processos para cultura de células
EP2113564A1 (en) * 2008-05-01 2009-11-04 Arecor Limited Protein formulation
WO2010020690A1 (en) 2008-08-21 2010-02-25 Octapharma Ag Recombinantly produced human factor viii and ix
CN102143759A (zh) * 2008-09-03 2011-08-03 奥克塔法马股份有限公司 重组制备的因子ⅷ的新型保护组合物
WO2010045321A2 (en) * 2008-10-15 2010-04-22 Baxter International Inc. Pegylation of recombinant blood coagulation factors in the presence of bound antibodies
NZ593190A (en) 2008-11-07 2013-01-25 Baxter Int Factor viii formulations
ES2669020T3 (es) 2008-12-31 2018-05-23 Revance Therapeutics, Inc. Formulaciones inyectables de toxina botulínica
MX362028B (es) 2009-02-03 2019-01-04 Amunix Pharmaceuticals Inc Polipeptidos recombinantes extendidos y composiciones que comprenden los mismos.
US10172950B2 (en) 2009-06-09 2019-01-08 Prolong Pharmaceuticals, LLC Hemoglobin compositions
DK3266463T3 (da) 2009-06-09 2024-01-08 Prolong Pharmaceuticals Llc Hæmoglobinsammensætninger
US10172949B2 (en) 2009-06-09 2019-01-08 Prolong Pharmaceuticals, LLC Hemoglobin compositions
MX344583B (es) 2009-06-25 2016-12-20 Revance Therapeutics Inc Formulaciones de toxina botulinica libres de albumina.
JP5908401B2 (ja) 2009-07-27 2016-04-26 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ 血液凝固タンパク質複合体
ES2856055T3 (es) 2009-07-27 2021-09-27 Baxalta GmbH Glicopolisialilación de proteínas diferentes de las proteínas de coagulación de la sangre
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
JP5909755B2 (ja) 2009-07-27 2016-04-27 リポクセン テクノロジーズ リミテッド 非血液凝固タンパク質の糖ポリシアル酸化
BR112012004094A2 (pt) 2009-08-24 2016-03-08 Amunix Operating Inc composições de fator vii de coagulação e métodos para fazer e usar as mesmas
GB0915480D0 (en) * 2009-09-04 2009-10-07 Arecor Ltd Stable formulation of factor viii
US8765432B2 (en) 2009-12-18 2014-07-01 Oligasis, Llc Targeted drug phosphorylcholine polymer conjugates
TR201908836T4 (tr) 2010-07-30 2019-07-22 Baxalta GmbH Oksim bağına yönelik nükleofilik katalizörler.
EP2635297B1 (en) 2010-11-05 2019-02-27 Baxalta GmbH A new variant of antihemophilic factor viii having increased specific activity
AU2011343813B2 (en) 2010-12-15 2015-05-21 Takeda Pharmaceutical Company Limited Eluate collection using conductivity gradient
KR20130125789A (ko) * 2010-12-16 2013-11-19 노보 노르디스크 에이/에스 수성 인자ⅷ 용액
EA032056B1 (ru) 2010-12-22 2019-04-30 Баксалта Инкорпорейтид Конъюгат терапевтического белка и производного жирной кислоты, способы получения конъюгата терапевтического белка и производного жирной кислоты (варианты)
CN111574632A (zh) 2012-02-15 2020-08-25 比奥贝拉蒂治疗公司 因子viii组合物及其制备和使用方法
EP3549953A1 (en) 2012-02-15 2019-10-09 Bioverativ Therapeutics Inc. Recombinant factor viii proteins
AU2013204754C1 (en) 2012-05-16 2018-10-11 Takeda Pharmaceutical Company Limited Nucleophilic Catalysts for Oxime Linkage
US9212357B2 (en) 2012-12-03 2015-12-15 Omrix Biopharmaceuticals Ltd. Thrombin solution and methods of use thereof
WO2014144549A1 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Factor ix polypeptide formulations
TWI629993B (zh) * 2013-03-15 2018-07-21 美商生物化學醫療公司 因子ｖｉｉｉ多肽調配物
US9700486B2 (en) 2013-04-24 2017-07-11 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
EP3033097B1 (en) 2013-08-14 2021-03-10 Bioverativ Therapeutics Inc. Factor viii-xten fusions and uses thereof
ES2819217T3 (es) 2013-09-08 2021-04-15 Kodiak Sciences Inc Conjugados de polímeros iónicos dipolares y factor VIII
NZ722391A (en) 2014-02-04 2022-12-23 Biogen Ma Inc Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications
EP3123090A4 (en) * 2014-03-24 2017-12-13 Bioverativ Therapeutics Inc. Lyophilized factor ix formulations
US12180264B2 (en) 2014-03-24 2024-12-31 R-Pharm Overseas, Inc. IL1-R1 derived inhibitor of IL-1β and use thereof
CN106413741A (zh) 2014-04-01 2017-02-15 爱德技术生物科学有限公司 含低糖‑甘氨酸的稳定因子viii制剂
KR20160146763A (ko) * 2014-04-01 2016-12-21 어드밴텍 바이오사이언스 파마큐티카 엘티디에이 부형제로서 칼슘이 첨가되지 않은 factor viii의 안정화
DK3193911T5 (da) * 2014-07-25 2024-10-14 Csl Behring Gmbh Forbedrede faktor VII-præparater til brug ved behandling af hæmofili A
US10238718B2 (en) * 2014-08-04 2019-03-26 Csl Limited Factor VIII formulation
MA40864A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
CN107847572A (zh) 2015-05-13 2018-03-27 艾吉纳斯公司 用于癌症治疗和预防的疫苗
AR104847A1 (es) 2015-06-17 2017-08-16 Lilly Co Eli Formulación de anticuerpo anti-cgrp
BR112018002150A2 (pt) 2015-08-03 2018-09-18 Bioverativ Therapeutics Inc proteínas de fusão do fator ix e métodos de fabricação e uso das mesmas
WO2017076967A1 (en) * 2015-11-05 2017-05-11 Novo Nordisk A/S Fviii formulation
EP3167877A1 (en) 2015-11-12 2017-05-17 Bayer Pharma Aktiengesellschaft Method for the production of freeze-dried pellets comprising factor viii
SG11201804666QA (en) 2015-12-03 2018-06-28 Baxalta Inc Factor viii with extended half-life and reduced ligand-binding properties
AU2017366709A1 (en) 2016-12-02 2019-07-18 Bioverativ Therapeutics Inc. Methods of treating hemophilic arthropathy using chimeric clotting factors
EP3694322B1 (en) 2017-10-09 2024-07-03 Terumo BCT Biotechnologies, LLC Lyophilization container and method of using same
EP3784688A2 (en) 2018-04-26 2021-03-03 Agenus Inc. Heat shock protein-binding peptide compositions and methods of use thereof
SG11202010767SA (en) 2018-05-18 2020-11-27 Bioverativ Therapeutics Inc Methods of treating hemophilia a
US11609042B2 (en) 2019-03-14 2023-03-21 Terumo Bct Biotechnologies, Llc Multi-part lyophilization container and method of use
KR20220029733A (ko) 2019-07-04 2022-03-08 체에스엘 베링 렝나우 아게 응고 인자 viii의 시험관내 안정성을 증가시키기 위한 절단된 폰 빌레브란트 인자 (vwf)
US11912784B2 (en) 2019-10-10 2024-02-27 Kodiak Sciences Inc. Methods of treating an eye disorder
CN115768787A (zh) * 2020-05-22 2023-03-07 阿法姆海外股份有限公司 IL1-R1衍生的IL-1β抑制剂及其用途
US20220380439A1 (en) 2020-11-09 2022-12-01 Takeda Pharmaceutical Company Limited Purification of fviii from plasma using silicon oxide adsorption
BR112023026782A2 (pt) * 2021-06-23 2024-03-12 Bioverativ Therapeutics Inc Formulações de proteínas quiméricas de fator viii e usos das mesmas
MX2024004494A (es) * 2021-10-15 2024-07-15 Bioverativ Therapeutics Inc Formulaciones de proteinas quimericas de factor viii y usos de las mismas.
CN115554418B (zh) * 2022-11-22 2023-04-14 四川至善唯新生物科技有限公司 一种重组腺相关病毒载体的药物组合物及其用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4165370A (en) * 1976-05-21 1979-08-21 Coval M L Injectable gamma globulin
US4783441A (en) * 1979-04-30 1988-11-08 Hoechst Aktiengesellschaft Aqueous protein solutions stable to denaturation
DE3176491D1 (en) * 1980-03-05 1987-11-26 Miles Lab Pasteurized therapeutically active protein compositions
US4481189A (en) * 1982-04-14 1984-11-06 New York Blood Center Inc. Process for preparing sterilized plasma and plasma derivatives
US4597966A (en) * 1985-01-09 1986-07-01 Ortho Diagnostic Systems, Inc. Histidine stabilized immunoglobulin and method of preparation
SE8501050D0 (sv) * 1985-03-05 1985-03-05 Kabivitrum Ab Biologically active fragments of human antihemophilic factor and method for preparation thereof
US4758657A (en) * 1985-07-11 1988-07-19 Armour Pharmaceutical Company Method of purifying Factor VIII:C
CA1292686C (en) * 1986-10-27 1991-12-03 Ze'ev Shaked Pharmaceutical compositions of recombinant interleukin-2 and formulation process
US4877608A (en) * 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
FR2630115B1 (fr) * 1988-04-14 1994-10-28 Merieux Inst Procede de stabilisation des solutions d'albumine humaine et solution obtenue
US5096885A (en) * 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
US4996047A (en) * 1988-11-02 1991-02-26 Richardson-Vicks, Inc. Sustained release drug-resin complexes
DE69010518T2 (de) * 1989-01-30 1994-11-03 Corint Ltd Wässerige Desmopressin-CMC enthaltende Arzneizubereitung.
SE465222C5 (sv) * 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
DE4001451A1 (de) * 1990-01-19 1991-08-01 Octapharma Ag Stabile injizierbare loesungen von faktor viii und faktor ix
DE4111393A1 (de) * 1991-04-09 1992-10-15 Behringwerke Ag Stabilisierte faktor viii-praeparationen
CZ290342B6 (cs) * 1992-10-02 2002-07-17 Genetics Institute Inc. Kompozice stabilní při skladování, obsahující koagulační faktor VIII a neiontovou povrchově aktivní látku a způsob její výroby

Also Published As

Publication number Publication date
ATE316981T1 (de) 2006-02-15
HUT70330A (en) 1995-09-28
DE69329795D1 (de) 2001-02-01
AU677797B2 (en) 1997-05-08
CZ132894A3 (en) 1994-11-16
NO942033D0 (no) 1994-06-01
HU211670A9 (en) 1995-12-28
SK282483B6 (sk) 2002-02-05
EP1652534A2 (en) 2006-05-03
CA2124690A1 (en) 1994-04-14
CA2124690C (en) 2007-09-11
ATE198277T1 (de) 2001-01-15
GR3035472T3 (en) 2001-05-31
WO1994007510A1 (en) 1994-04-14
FI111443B (fi) 2003-07-31
US5733873A (en) 1998-03-31
ES2154650T3 (es) 2001-04-16
EP1016673A1 (en) 2000-07-05
NO942033L (no) 1994-06-01
EP0627924B1 (en) 2000-12-27
DE69333974T2 (de) 2006-08-03
SK65994A3 (en) 1995-03-08
FI942573L (fi) 1994-06-01
JPH07501560A (ja) 1995-02-16
DE69329795T2 (de) 2001-07-05
EP1016673B1 (en) 2006-02-01
DE69333974D1 (de) 2006-04-13
US5919766A (en) 1999-07-06
MX9306133A (es) 1994-04-29
EP1652534A3 (en) 2007-05-02
EP0627924A1 (en) 1994-12-14
HU220194B (hu) 2001-11-28
FI942573A0 (fi) 1994-06-01
PT627924E (pt) 2001-05-31
CZ290342B6 (cs) 2002-07-17
AU5288393A (en) 1994-04-26
KR100303872B1 (ko) 2001-11-22
NZ256921A (en) 1996-05-28
HU9401382D0 (en) 1994-08-29
JP3905921B2 (ja) 2007-04-18

Similar Documents

Publication Publication Date Title
DK0627924T3 (da) Sammensætning, der omfatter koagulationsfaktor VIII formulering, fremgangsmåde til dens fremstilling og anvendelse af et overfladeaktivt middel som stabilisator
ATE121125T1 (de) Giessbare sulfon- peroxycarbonsäurezusammensetzung.
DE69133576D1 (de) Verfahren zur Herstellung von Enantiomerisch reine Beta-D-Dioxolan-Nukleoside
CA2149320A1 (en) Aqueous cleaning and bleaching composition containing hydrophobic liquid, h2o2 and two nonionic surfactants with different hlbs
DE69413167D1 (de) Peptid-Phosphinyloxymethyl-Ketonen als Inhibitoren von Interleukin-1 beta-konvertierenden Enzymen
ATE269290T1 (de) Benzoylderivate
DK31092D0 (da) 2-pyrimidinyl-1-piperazin-derivater, deres fremstilling og anvendelse
ES2089792T3 (es) Composiciones detergentes liquidas para superficies duras que contienen tensioactivos hibridos y cationicos y monoetanolamina y/o beta-aminoalcanol.
DK1075284T3 (da) Anvendelse af et vitalt farvestof til at lette kirugiske indgreb i forbindelse med vitreoretinal kurugi
ATE78397T1 (de) Verwendung von p-chlorophenoxyazetat von n,ndimethylbiguanidzur behandlung von neuropathien und nervendegeneration.
DK0585707T3 (da) Anvendelse af sølvlegeringer som kadmiumfri hårdlodningsmaterialer
DK259589D0 (da) Joderede, ikke-ioniske trijodbenzenforbindelser og kontrastmiddel indeholdende dem
DK0550493T3 (da) Anthelmintiske og anticoccidiske 3-carbamoyl-4-hydroxycoumariner, fremgangsmåde til deres anvendelse og sammensætninger
NO893141L (no) Toey-kondisjoneringsmidler.
ATE202697T1 (de) Reinigungsmittel, enthaltend farbstabilisator(en) und tensid(e)
ATE428692T1 (de) 24-schwefel-substituierte 1-alpha-25-dihydroxy- vitamin-d3-analogen
ES2104783T3 (es) Procedimiento para la purificacion de estreptolisina o, estreptolisina o intacta obtenible segun este procedimiento y su utilizacion.
ATE231001T1 (de) Verwendung von protein c inhibitor zur behandlung disseminierter intravasaler gerinnung (dic)
DK0417875T3 (da) 1-methoxypyrimidinyl-1H-1,2,4-triazol-3-sulfonsyrenitroanilider, fremgangsmåde til fremstilling heraf og deres anvendelse som middel med herbicid virkning
ES2143453T3 (es) Uso de derivados de dihidropiridina para la profilaxis o el tratamiento de trastornos de la circulacion cerebral.
EE03284B1 (et) Pestitsiidse toimega ühendid, nende valmistamise protsess, neid sisaldavad koostised ja meetod nende kasutamiseks
DE59202433D1 (de) Verfahren zur Herstellung von Benzolsulfonamiden.